Trial Profile

A clinical trial of ADXS-HOT

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 25 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ADXS-HOT (Primary)
Indications Cancer
Focus Adverse reactions

Most Recent Events

19 Jan 2023 According to an Ayala Pharmaceuticals media release, Advaxis merged with Ayala Pharmaceuticals to form Ayala Pharmaceuticals.
22 Jul 2019 New trial record
27 Jun 2019 According to an Advaxis Media release, the company plans to advance ADXS-HOT program into clinical trial in 2020(over the next 18 months).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com